NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$39.52
+0.50 (+1.28 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.00
$39.57
50-Day Range
$38.39
$40.66
52-Week Range
$33.26
$42.40
Volume4.15 million shs
Average Volume5.21 million shs
Market Capitalization$106.41 billion
P/E Ratio14.48
Dividend Yield5.30%
Beta0.7
30 days | 90 days | 365 days | Advanced Chart
Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GlaxoSmithKline and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline logo

About GlaxoSmithKline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

511th out of 2,218 stocks

Pharmaceutical Preparations Industry

255th out of 869 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

Is GlaxoSmithKline a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline
or view top-rated stocks.

What stocks does MarketBeat like better than GlaxoSmithKline?

Wall Street analysts have given GlaxoSmithKline a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlaxoSmithKline wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a decrease in short interest in June. As of June 30th, there was short interest totaling 14,450,000 shares, a decrease of 22.4% from the June 15th total of 18,630,000 shares. Based on an average daily volume of 4,580,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 0.6% of the company's stock are short sold.
View GlaxoSmithKline's Short Interest
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for GlaxoSmithKline
.

How can I listen to GlaxoSmithKline's earnings call?

GlaxoSmithKline will be holding an earnings conference call on Wednesday, July 28th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) announced its earnings results on Wednesday, April, 28th. The pharmaceutical company reported $0.63 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.63. The pharmaceutical company earned $10.23 billion during the quarter, compared to the consensus estimate of $10.66 billion. GlaxoSmithKline had a net margin of 16.01% and a trailing twelve-month return on equity of 24.57%.
View GlaxoSmithKline's earnings history
.

How has GlaxoSmithKline's stock been impacted by COVID-19 (Coronavirus)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GSK shares have decreased by 0.9% and is now trading at $39.52.
View which stocks have been most impacted by COVID-19
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Wednesday, May 5th. Stockholders of record on Friday, May 21st will be given a dividend of $0.6367 per share on Thursday, July 8th. This represents a $2.55 dividend on an annualized basis and a dividend yield of 6.44%. The ex-dividend date is Thursday, May 20th. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.63.
View GlaxoSmithKline's dividend history
.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.07 per share and currently has a dividend yield of 5.30%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of GlaxoSmithKline is 69.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 69.23% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Emma N. Walmsley, Chief Executive Officer & Executive Director
  • Iain James Mackay, Chief Financial Officer & Executive Director
  • Jon Ellis, VP & Head-Technology Business Development
  • Karenann K. Terrell, Chief Digital & Technology Officer
  • Hal V. Barron, Executive Director & Chief Scientific Officer

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), The Walt Disney (DIS) and NVIDIA (NVDA).

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.02%), Clean Yield Group (0.01%), Signature Wealth Management Group (0.00%), Old Port Advisors (0.00%), Hohimer Wealth Management LLC (0.00%) and Raymond James Trust N.A. (0.00%).
View institutional ownership trends for GlaxoSmithKline
.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Hoertkorn Richard Charles, Raymond James Trust N.A., Capital Investment Advisory Services LLC, Signature Wealth Management Group, Sound Income Strategies LLC, Gofen & Glossberg LLC IL, Gradient Investments LLC, and Welch & Forbes LLC.
View insider buying and selling activity for GlaxoSmithKline
or view top insider-selling stocks.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Brookstone Capital Management, Cardinal Capital Management, Clean Yield Group, Integrated Investment Consultants LLC, Meridian Wealth Management LLC, Hohimer Wealth Management LLC, Sequoia Financial Advisors LLC, and Independence Bank of Kentucky.
View insider buying and selling activity for GlaxoSmithKline
or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $39.52.

How much money does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $106.41 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.

How many employees does GlaxoSmithKline have?

GlaxoSmithKline employs 94,066 workers across the globe.

When was GlaxoSmithKline founded?

GlaxoSmithKline was founded in 2000.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

Where are GlaxoSmithKline's headquarters?

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 442080475000 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.